

Status: Currently Official on 13-Feb-2025  
Official Date: Official as of 01-Dec-2015  
Document Type: USP Monographs  
DocId: GUID-CD737773-73C9-43DE-830E-EA7AD5F9F59B\_1\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M8100\\_01\\_01](https://doi.org/10.31003/USPNF_M8100_01_01)  
DOI Ref: ipc7e

© 2025 USPC  
Do not distribute

## Benzocaine Topical Solution

### DEFINITION

Benzocaine Topical Solution is a solution of Benzocaine in a suitable solvent. It contains NLT 90.0% and NMT 110.0% of the labeled amount of benzocaine ( $C_9H_{11}NO_2$ ). It contains a suitable antimicrobial agent.

### IDENTIFICATION

- A.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

### ASSAY

#### PROCEDURE

**Solution A:** 0.1% Trifluoroacetic acid, prepared by diluting 1.0 mL of trifluoroacetic acid with water to 1 L

**Solution B:** Acetonitrile

**Mobile phase:** See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	90	10
34	50	50
35	90	10
38	90	10

**Diluent:** *Solution A* and *Solution B* (1:1)

**System suitability solution:** 1 µg/mL of [USP Benzocaine RS](#) and 2 µg/mL each of [USP Aminobenzoic Acid RS](#) and [USP Ethyl 4-Nitrobenzoate RS](#) in *Diluent*

**Standard solution:** 0.1 mg/mL of [USP Benzocaine RS](#) in *Diluent*

**Sample solution:** Nominally 0.1 mg/mL of benzocaine in *Diluent* prepared as follows. Transfer 10 mg of benzocaine from a portion of Topical Solution to a 100-mL volumetric flask, and dilute with *Diluent* to volume. Pass through a suitable filter of 0.45-µm pore size as needed, discarding the first 2–3 mL of filtrate.

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 280 nm. For *Identification* test A, use a diode array detector in the range of 200–400 nm.

**Column:** 4.6-mm × 25-cm; 5-µm packing L7

**Flow rate:** 1.5 mL/min

**Injection volume:** 20 µL

#### System suitability

**Samples:** *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for aminobenzoic acid, benzocaine, and ethyl 4-nitrobenzoate are 0.3, 1.0, and 2.1, respectively.]

#### Suitability requirements

**Resolution:** NLT 6 between aminobenzoic acid and benzocaine; and between benzocaine and ethyl 4-nitrobenzoate, *System suitability solution*

**Tailing factor:** NMT 1.5, *Standard solution*

**Relative standard deviation:** NMT 1.0%, *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of benzocaine ( $C_9H_{11}NO_2$ ) in the portion of Topical Solution taken:

- $r_U$  = peak response of benzocaine from the *Sample solution*
- $r_S$  = peak response of benzocaine from the *Standard solution*
- $C_S$  = concentration of [USP Benzocaine RS](#) in the *Standard solution* (mg/mL)
- $C_U$  = nominal concentration of benzocaine in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

**IMPURITIES**

- **ORGANIC IMPURITIES**  
**Solution A:** 0.1% Trifluoroacetic acid, prepared by diluting 1.0 mL of trifluoroacetic acid with water to 1 L  
**Solution B:** Acetonitrile  
**Mobile phase:** See [Table 2](#).

**Table 2**

Time (min)	Solution A (%)	Solution B (%)
0	85	15
34	55	45
35	85	15
38	85	15

- Diluent:** *Solution A* and *Solution B* (1:1)
- Standard solution:** 1 µg/mL of [USP Benzocaine RS](#) and 2 µg/mL each [USP Aminobenzoic Acid RS](#) and [USP Ethyl 4-Nitrobenzoate RS](#) in *Diluent*
- Sample solution:** Nominally 1 mg/mL of benzocaine in *Diluent* prepared as follows. Transfer 50 mg of benzocaine from a portion of Topical Solution to a volumetric flask and dissolve with aid of sonication as needed, then dilute with *Diluent* to volume. Pass through a suitable filter of 0.45-µm pore size as needed, discarding the first 2–3 mL of filtrate.
- Chromatographic system**  
(See [Chromatography \(621\), System Suitability](#).)
- Mode:** LC
- Detector:** UV 280 nm
- Column:** 4.6-mm × 25-cm; 5-µm packing L7
- Flow rate:** 1.5 mL/min
- Injection volume:** 20 µL
- System suitability**
- Sample:** *Standard solution*
- [NOTE—See [Table 3](#) for relative retention times.]
- Suitability requirements**
- Resolution:** NLT 6 between aminobenzoic acid and benzocaine; and between benzocaine and ethyl 4-nitrobenzoate
- Relative standard deviation:** NMT 2.0% for each peak corresponding to benzocaine, aminobenzoic acid, and ethyl 4-nitrobenzoate
- Analysis**
- Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of aminobenzoic acid and ethyl 4-nitrobenzoate in the portion of Topical Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

- $r_U$  = peak response of aminobenzoic acid or ethyl 4-nitrobenzoate from the *Sample solution*
- $r_S$  = peak response of aminobenzoic acid or ethyl 4-nitrobenzoate from the *Standard solution*
- $C_S$  = concentration of [USP Aminobenzoic Acid RS](#) or [USP Ethyl 4-Nitrobenzoate RS](#) in the *Standard solution* (mg/mL)
- $C_U$  = nominal concentration of benzocaine in the *Sample solution* (mg/mL)

Calculate the percentage of any other individual unspecified impurity in the portion of Topical Solution taken:

$r_U$  = peak response of any other individual unspecified impurity from the *Sample solution*

$r_S$  = peak response of benzocaine from the *Standard solution*

$C_S$  = concentration of [USP Benzocaine RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of benzocaine in the *Sample solution* (mg/mL)

**Acceptance criteria:** See [Table 3](#). Disregard peaks less than 0.05%.

**Table 3**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Aminobenzoic acid	0.27	0.20
Benzocaine	1.0	—
Ethyl 4-nitrobenzoate	2.5	0.20
Any other individual unspecified impurity	—	0.10
Total impurities	—	1.0

**SPECIFIC TESTS**

• [MICROBIAL ENUMERATION TESTS \(61\)](#) and [TESTS FOR SPECIFIED MICROORGANISMS \(62\)](#): It meets the requirements of the tests for absence of *Staphylococcus aureus* and *Pseudomonas aeruginosa*.

**ADDITIONAL REQUIREMENTS**

• **PACKAGING AND STORAGE:** Preserve in tight containers, protected from light, and avoid prolonged exposure to temperatures exceeding 30°.

• [USP REFERENCE STANDARDS \(11\)](#).

[USP Aminobenzoic Acid RS](#)

Benzoic acid, 4-amino.  
 $C_7H_7NO_2$  137.14

[USP Benzocaine RS](#)

[USP Ethyl 4-Nitrobenzoate RS](#)

Benzoic acid, 4-nitro-, ethyl ester.  
 $C_9H_9NO_4$  195.17

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
BENZOCAINE TOPICAL SOLUTION	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 40(4)

**Current DocID:** GUID-CD737773-73C9-43DE-830E-EA7AD5F9F59B\_1\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M8100\\_01\\_01](https://doi.org/10.31003/USPNF_M8100_01_01)

**DOI ref:** [ipc7e](#)